Skip to main content

Table 2 Factors associated with the recurrence of HCC after DAA treatment in the overall period

From: AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy

 

HCC recurrence

No HCC recurrence

Hazard ratio

95% CI

p-value

Age (years)

71.9 ± 8.1

71.5 ± 8.1

1.00

0.98–1.03

0.71

Sex (male/female)

70/27

56/46

1.70

1.09–2.66

0.013

Body mass index (kg/m2)

23.1 ± 3.0

23.3 ± 3.5

0.98

0.92–1.05

0.79

White blood cell count (/μL)

4359 ± 1529

4235 ± 1207

1.00

0.99–1.00

0.52

Platelet count (×104/μL)

12.3 ± 10.5

11.4 ± 4.6

1.00

0.98–1.02

0.43

ALT (U/L)

48.9 ± 32.5

45.4 ± 28.2

1.00

0.99–1.00

0.42

AST (U/L)

53.5 ± 25.7

51.1 ± 27.6

1.00

0.99–1.00

0.52

Total bilirubin (mg/dL)

0.8 ± 0.4

0.8 ± 0.4

0.96

0.61–1.52

0.89

Albumin (g/dL)

3.7 ± 0.4

3.8 ± 0.4

0.68

0.42–1.11

0.35

Prothrombin time (%)

83.3 ± 13.9

82.6 ± 16.8

1.00

0.99–1.01

0.78

AFP (ng/mL)

22.5 ± 58.8

19.1 ± 46.8

1.00

0.99–1.00

0.65

eGFR (mL/min/1.73 m2)

66.1 ± 19.5

69.1 ± 21.0

0.99

0.98–1.00

0.31

Total cholesterol (mg/dL)

151 ± 29.0

151 ± 26.8

1.00

0.99–1.00

0.96

Diabetes mellitus (no/yes)

68/28

81/21

1.43

0.92–1.00

0.18

Alcohol (none/drinking/unknown)

69/12/21

83/10/4

0.90

0.59–1.38

0.18

FIB-4 index

5.9 ± 3.8

5.7 ± 3.6

1.01

0.96–1.07

0.62

APRI

1.6 ± 1.5

1.5 ± 1.5

1.04

0.92–1.16

0.56

Post-treatment white blood cell count (/μL)

4845 ± 1434

4599 ± 1576

1.00

0.99–1.00

0.26

Post-treatment ALT (U/L)

21.3 ± 10.3

24.1 ± 29.4

0.99

0.97–1.00

0.39

Post-treatment AST (U/L)

28.8 ± 12.3

29.9 ± 19.5

0.99

0.98–1.00

0.64

Post-treatment total bilirubin (mg/dL)

0.8 ± 0.4

0.8 ± 0.3

0.98

0.60–1.58

0.72

Post-treatment albumin (g/dL)

3.9 ± 0.4

3.9 ± 0.3

0.76

0.48–1.21

0.56

Post-treatment prothrombin time (%)

83.2 ± 14.1

83.9 ± 17.2

1.00

0.98–1.01

0.76

Post-treatment AFP (ng/mL)

9.7 ± 13.0

6.4 ± 6.3

1.03

0.99–1.05

0.11

Post-treatment eGFR (mL/min/1.73 m2)

63.0 ± 18.7

67.9 ± 19.8

0.98

0.97–1.00

0.10

SVR/no SVR

86/11

98/4

2.55

1.35–4.80

0.048

Child-Pugh class (A/B/C)

78/13/1

83/13/0

1.17

0.68–2.02

0.58

BCLC stage (0/A/B/C/D)

37/25/28/16/1

44/24/13/19/2

1.06

0.90–1.25

0.75

Number of months from HCC treatment to DAA therapy initiation

17 ± 25

23 ± 26

1.00

0.99–1.00

0.12

Number of curative treatments for HCC

1.4 ± 1.6

0.8 ± 1.3

1.23

1.09–1.38

0.004